Previous 10 | Next 10 |
LEXINGTON, Mass. , March 14, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the fourth qu...
LEXINGTON, Mass., March 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced ...
Agenus ( AGEN ) is a biotechnology pharmaceutical company with one commercial product and a broad pipeline of potential therapies. It has licensed potential cancer therapies to several larger pharmaceutical companies. The stock plummeted last week, from $3.63 on the prior Friday and to close a...
LEXINGTON, Mass. , Feb. 19, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security ...
LEXINGTON, Mass. , Feb. 15, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST),...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
"Marge" Bests Herceptin The treatment of HER2+ breast cancer was revolutionized by approval of Roche's (RHHBY) Herceptin (trastuzumab) in the late 90s. In the past two decades, Herceptin has saved thousands of lives and registered over $75 billion in global sales. Since that time, HER2 h...
February 5, 2019 Palm Beach, FL – (February 5, 2018) – Considering that yesterday, February 4, was World Cancer Day, it is encouraging that the private sector and the U.S. government are mutually trying to solve a serious problem and are in fact, working closely and in harm...
NEW YORK , Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Ag...
LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today, the upcoming launch of its Biotech Electronic Sec...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...